BioSig Technologies Files 8-K for Material Definitive Agreement
Ticker: STEX · Form: 8-K · Filed: Dec 18, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $8,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, 8-k
TL;DR
BioSig just signed a big deal, filing an 8-K. Details TBD.
AI Summary
On December 18, 2024, BioSig Technologies, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Los Angeles, California, filed this 8-K report detailing the agreement. Specific details of the agreement, including financial terms and parties involved, are not fully disclosed in the provided text.
Why It Matters
This filing indicates a significant business development for BioSig Technologies, Inc., potentially impacting its operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — The filing of a material definitive agreement suggests a significant event, but the lack of specific details in the provided text introduces uncertainty.
Key Numbers
- 001-38659 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-4333375 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- BioSig Technologies, Inc. (company) — Registrant
- December 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Los Angeles, California (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by BioSig Technologies, Inc. on December 18, 2024?
The provided text states that BioSig Technologies, Inc. entered into a material definitive agreement on December 18, 2024, but does not specify the nature of the agreement.
Who are the other parties involved in this material definitive agreement?
The provided text does not disclose the names of the other parties involved in the material definitive agreement.
What are the key financial terms or obligations associated with this agreement?
The provided text does not contain information regarding the financial terms or obligations of the material definitive agreement.
What is the principal business address of BioSig Technologies, Inc. as reported in this filing?
The principal executive offices of BioSig Technologies, Inc. are located at 12424 Wilshire Blvd, Suite 745, Los Angeles, California, 90025.
What is the filing date and the earliest event date reported in this 8-K?
The filing date and the date of the earliest event reported are both December 18, 2024.
Filing Stats: 1,235 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2024-12-18 16:30:32
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
- $8,500,000 — uance and sale of up to an aggregate of $8,500,000 of shares of the Company's common stock
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex5-1.htm (EX-5.1) — 11KB
- ex10-1.htm (EX-10.1) — 280KB
- ex5-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-24-050607.txt ( ) — 578KB
- bsgm-20241218.xsd (EX-101.SCH) — 3KB
- bsgm-20241218_lab.xml (EX-101.LAB) — 33KB
- bsgm-20241218_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: December 18, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer